Top Markets
Coin of the day
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rank in Stocks #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.7426
Last synced: 2026-08-21
Market Cap
$69.05M
Change (1 day)
-2.17%
Change (1 year)
-57.57%
Country
US
Trade Citius Oncology, Inc. (CTOR)

Category

Operating Margin for Citius Oncology, Inc. (CTOR)
Operating Margin as of 2026 TTM: 0.00%
According to Citius Oncology, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Citius Oncology, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
43.92% -
US
26.81% -
US
29.32% -
US
26.59% -
CH
16.65% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.